TP53 and B-cell chronic lymphocytic leukemia: CLL diagnosis and monitoring rely on immunophenotyping, while the characterization of molecular biomarkers such as TP53 disruption, NOTCH1 mutation, immunoglobulin heavy chain variable region (IGHV) gene mutational status, and other genetic aberrations provides important parameters for CLL prognostication [43,44,45,46,47].